Folic acid supplementation (1mg/d) is the standard recommendation for Canadian children with Sickle cell disease (SCD), even though it can provide up to six times the recommended intake amount for healthy children. There is growing concern that too much folic acid can be detrimental to health as high folate levels and circulating unmetabolized folic acid (UMFA), which occurs in blood with doses of folic acid as low as 0.2mg/d, have been associated with accelerated growth of some pre-cancerous cells, and altered DNA methylation and gene expression. To inform the efficacy and potential harm of high-dose folic acid supplementation in Canadian children with SCD, a double-blind randomized controlled cross-over trial is proposed. Children with SCD (n=36, aged 2-19 y) will be recruited from BC Children's Hospital and randomized to initially receive 1 mg/d folic acid or a placebo for 12-weeks (wk). After a 12-wk washout period, treatments will be reversed.
Blood samples will be collected at baseline and 12-wk of each treatment period (weeks 12, 24, and 36). Serum and RBC concentrations of total folate, different folate forms and clinical outcomes will be measured at baseline and after each treatment period. Dietary folate intake will be assessed at baseline. The objective of this study is to determine efficacy and potential harm of folic acid supplementation, versus no supplementation, in Canadian children with sickle cell disease. It is hypothesized that: (1) there will be no difference in mean RBC folate concentrations across folic acid and placebo groups after 12-wk, (2) none of the participants will have folate deficiency, and (3) compared to periods of no supplementation, during periods of high-dose folic acid supplementation participants will show no difference in clinical outcomes, but have higher plasma unmetabolized folic acid concentrations. Significance: There is a need to determine if the current clinical practice of high-dose folic acid supplementation is efficacious, and warranted.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE
Enrollment
31
1 milligram folic acid
Placebo
BC Children's Hospital
Vancouver, British Columbia, Canada
Red Blood Cell Folate Concentration
Biochemical folate status marker (nmol/L)
Time frame: 12 weeks
Red Blood Cell Folate Concentration
Biochemical folate status marker (nmol/L)
Time frame: 36 weeks
Serum Folate Concentration
Biochemical folate status marker (nmol/L)
Time frame: 12 weeks
Serum Folate Concentration
Biochemical folate status marker (nmol/L)
Time frame: 36 weeks
Plasma Unmetabolized Folic Acid Concentration
Biochemical folate marker (nmol/L)
Time frame: 12 weeks
Plasma Unmetabolized Folic Acid Concentration
Biochemical folate marker (nmol/L)
Time frame: 36 weeks
S-adenosyl-methionine Concentration
Biochemical folate metabolite (µmol/L)
Time frame: 12 weeks
S-adenosyl-methionine Concentration
Biochemical folate metabolite (µmol/L)
Time frame: 36 weeks
S-adenosyl-homocysteine Concentration
Biochemical folate metabolite (µmol/L)
Time frame: 12 weeks
S-adenosyl-homocysteine Concentration
Biochemical folate metabolite (µmol/L)
Time frame: 36 weeks
Total homocysteine Concentration
Biochemical folate metabolite (µmol/L)
Time frame: 12 weeks
Total homocysteine Concentration
Biochemical folate metabolite (µmol/L)
Time frame: 36 weeks
Acute Pain Crises
Participant self-reported occurrence (# of episodes, and severity of episodes)
Time frame: 12 weeks
Acute Pain Crises
Participant self-reported occurrence (# of episodes, and severity of episodes)
Time frame: 36 weeks
Megaloblastic anemia
Determined by hemoglobin and Mean Corpuscular Volume (MCV) concentrations below/above age-specific hematological cut-offs
Time frame: 12 weeks
Megaloblastic anemia
Determined by hemoglobin and Mean Corpuscular Volume (MCV) concentrations below/above age-specific hematological cut-offs
Time frame: 36 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.